<p data-start="65" data-end="329">According to analysts, the market for ELISA tests to determine prostate-specific antigen (PSA) is rapidly growing. In 2024, its volume is expected to reach approximately $4.15 billion, and by 2025, around $4.66 billion, reflecting an annual growth rate of 12.1%.</p>
<p data-start="331" data-end="367">? <strong data-start="334" data-end="365">Key Factors Driving Growth:</strong></p>

<ul data-start="368" data-end="897">
 	<li data-start="368" data-end="471">Increasing life expectancy and an aging population, leading to a higher number of at-risk patients.</li>
 	<li data-start="472" data-end="536">Rising awareness of the importance of preventive screenings.</li>
 	<li data-start="537" data-end="764">Improved clinical guidelines for prostate cancer screening and monitoring, both internationally and in Ukraine. Notably, PSA level testing is expected to be included in Ukraine’s Medical Guarantees Program starting in 2025.</li>
 	<li data-start="765" data-end="897">Advancements in pharmaceuticals and medical technologies that contribute to a comprehensive approach to diagnosis and treatment.</li>
</ul>
<p data-start="899" data-end="950">? <strong data-start="902" data-end="948">Prostate Cancer in Ukraine: Key Statistics</strong></p>
<p data-start="952" data-end="1047">According to the <em data-start="969" data-end="1044">National Cancer Registry Bulletin No. 25 – “Cancer in Ukraine, 2022–2023”</em>:</p>

<ul data-start="1048" data-end="1532">
 	<li data-start="1048" data-end="1267">Excluding non-melanoma skin cancers, 52.3% of malignant neoplasms (MN) in men are attributed to lung, prostate, colorectal, and stomach cancers. These same diseases account for 54.6% of cancer-related deaths in men.</li>
 	<li data-start="1268" data-end="1404">Prostate cancer accounts for <strong data-start="1299" data-end="1308">13.2%</strong> of all malignant neoplasms in men, making it the second most common cancer after lung cancer.</li>
 	<li data-start="1405" data-end="1532">Prostate cancer has one of the lowest survival rates, as treatment is significantly less effective in late-stage diagnoses.</li>
</ul>
<p data-start="1534" data-end="1593">❓ <strong data-start="1536" data-end="1591">Why Are Early PSA Screening and Monitoring Crucial?</strong></p>
<p data-start="1595" data-end="1848">✅ In its early stages, prostate cancer is much more treatable, while late-stage diagnosis drastically reduces the effectiveness of therapy. Regular preventive screenings and PSA level testing are critical in lowering mortality rates from this disease.</p>
<p data-start="1850" data-end="2028">✅ The rapid growth of the global PSA testing market and the concerning cancer statistics in Ukraine highlight the urgent need for <strong data-start="1980" data-end="2025">accessible and reliable screening methods</strong>.</p>
<p data-start="2030" data-end="2299" data-is-last-node="" data-is-only-node="">✅ <strong data-start="2032" data-end="2059">ELISA-based PSA testing</strong> enables medical institutions of all levels to optimize diagnostics by providing a balance of <strong data-start="2153" data-end="2196">accuracy, speed, and cost-effectiveness</strong>. As a result, it significantly improves the chances of successful treatment for thousands of patients.</p>